Clinical trials: NASH (Non-Alcoholic Steatohepatitis)
Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH)
Non-alcoholic Fatty Liver Disease Parametric PET (FLiPP) Study
The goal of this study is to evaluate non-invasive imaging techniques for determining liver steatosis (fat), inflammation (abnormal tissue swelling), and fibrosis (abnormal tissue scarring).In addition, the study group will be…
- Trial name
- FLiPP (NCT02754037)
- Testing
- Fluorodeoxyglucose (FDG) positron emission tomography (PET), Magnetic resonance imaging (MRI), PET Explorer
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of California, Davis
Liver Fibrosis
A Potential Novel Marker for Liver Fibrosis in NASH: the Soluble Secreted Form of the Human Asialoglycoprotein Receptor
Soluble secreted proteins that are expressed uniquely in specific organs and whose formation of secretion is regulated by disease states are excellent markers for the disease.
- Trial name
- NCT00941902
- Where
- Israel
- Volunteers
- 148 people
- Sponsor
- Ziv Hospital
Chronic Liver Disease
An Observational Study Evaluating Patients With Chronic Liver Diseases Associated With Hepatic Steatosis
Hepatic steatosis may cause inflammation and fibrosis within the liver potentially leading to end-stage liver disease cirrhosis, liver failure and death.
- Trial name
- FALL (NCT05335603)
- Where
- Denmark
- Volunteers
- 335 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Fatty Liver, Nonalcoholic, Diabetes Mellitus, Type 2
Anti-diabetic Drugs and Fatty Liver Management
Type 2 DM is one of the major risk factors for development of non-alcoholic fatty liver disease. The pooled prevalence of fatty liver among diabetics is 54% (95% CI 45%-64%).
- Trial name
- NCT05041673
- Testing
- Metformin
- Where
- Egypt
- Volunteers
- 120 people
- Sponsor
- Alexandria University
Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis
This is a phase 2 randomized, double-blind, placebo-controlled parallel group study of 3 dose levels of HU6 in subjects with nonalcoholic steatohepatitis (NASH).
- Conditions
- Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Fatty Liver
- Trial name
- NCT05979779
- Testing
- HU6
- Where
- 20 sites in United States
- Volunteers
- 219 people
- Sponsor
- Rivus Pharmaceuticals, Inc.
Hepatic Steato-Fibrosis, Non-Alcoholic Fatty Liver Disease
MASLD in Primary Hypothyroidism and Efficacy of Dapaglifozin
Non-alcoholic fatty liver disease (NAFLD) is a global epidemic with a prevalence of 25-40%.Primary Hypothyroidism is one of Endocrinopathies who are at risk of developing NAFLD/NASH and estimated prevalence of Primary…
- Trial name
- SHIELD (NCT06373523)
- Testing
- Dapagliflozin 10mg Tab, Levothyroxine Replacement daily
- Where
- India
- Volunteers
- 50 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Non-alcoholic Steatohepatitis
Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH)
A randomized, double-blind, placebo-controlled Phase II study，to evaluate the efficacy and safety of TQA2225/AP025 in Patients With Non-Alcoholic Steatohepatitis (NASH)
- Trial name
- NCT06569524
- Where
- 53 sites in China
- Volunteers
- 120 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
NAFLD
A Gender and Culturally Specific Approach to Reduce NAFLD in Mexican-American Men
Using a small Randomized Controlled Trial (RCT) study design, PNPLA3 risk allele carriers (CG/GG genotype) with NAFLD, will be assigned 2:1 to a tailored NAFLD-specific weight loss intervention compared to a wait-list control…
- Trial name
- NCT04186260
- Testing
- NAFLD-specific weight loss intervention, Wait-list control
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of Arizona
NASH
Trial of CS060380 Tablets for Non-alcoholic Steatohepatitis (NASH)
The goal of this clinical trial is to learn if CS060380 tablets works to treat non-alcoholic steatohepatitis(NASH) in adults.It will also learn about the safety of CS060380 tablets.The main questions it aims to answer are: After…
- Trial name
- NCT07198386
- Testing
- CS060380
- Where
- 8 sites in China
- Volunteers
- 120 people
- Sponsor
- Cascade Pharmaceuticals, Inc
Non-Alcoholic Fatty Liver Disease
Diet and Meal Timing in Patients With Metabolic Dysfunction Associated Steatoic Liver Disease
This study will assess the impact of time-restricted eating (8 hours of eating each day) with standard of care lifestyle recommendations (hypocaloric, Mediterranean diet and 30 minutes of exercise on at least 5 days/week) on the…
- Trial name
- NCT05332613
- Testing
- TRE plus SOC, SOC, TRE
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Non-alcoholic Steatohepatitis (NASH)
Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant
The primary objective of this study is to determine the effect of hepatic impairment on the pharmacokinetics (PK) of miricorilant following a single oral dose by comparing participants with normal hepatic function with…
- Trial name
- NCT05553470
- Testing
- Miricorilant
- Where
- 3 sites in United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Corcept Therapeutics
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)
Phase 2a, dose-ranging Study with PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)
- Trial name
- NCT03248882
- Testing
- PF-05221304
- Where
- 140 sites in United States, Australia and 4 more
- Volunteers
- 305 people
- Sponsor
- Pfizer
Non-Alcoholic Steatohepatitis (NASH)
Tolerability, Efficacy, and PK of ZSP1601 in Patients With Non-Alcoholic Steatohepatitis (NASH)
Double-blind, randomized, placebo-controlled study to explore the safety, tolerability PK characteristics and early efficacy of ZSP1601 tablets in patients with non-alcoholic steatohepatitis (NASH).
- Trial name
- NCT04140123
- Testing
- ZSP1601
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Guangdong Raynovent Biotech Co., Ltd
Non-Alcoholic Fatty Liver Disease, Glucagon Resistance
The Effect of Lifestyle-induced Hepatic Steatosis on Glucagon-stimulated Amino Acid Turnover
Many patients with type 2 diabetes exhibit elevated plasma concentrations of the glucose-mobilising pancreatic hormone glucagon; i.e. hyperglucagonaemia.
- Trial name
- NCT04859322
- Testing
- Glucagon
- Where
- Denmark
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Malte Palm Suppli, MD
Non-Alcoholic Fatty Liver Disease
Porphyromonas Gingivalis and Severity of Fibrosis in Patients With Non-alcoholic Fatty Liver Disease
Many studies suggest that Porphyromonas gingivalis, a virulent periodontopathogenic bacterium, is associated with many systemic diseases such as cardiovascular diseases.
- Trial name
- BUCCONAFLD (NCT05654129)
- Testing
- saliva samples, medical questionnaire
- Where
- France
- Volunteers
- 182 people
- Sponsor
- University Hospital, Toulouse
Nonalcoholic Steatohepatitis
JKB-121 for the Treatment of Nonalcoholic Steatohepatitis
To evaluate the safety and potential efficacy of two dose levels of JKB-121 (5 mg twice daily and 10 mg twice daily) in reducing liver fat and/or liver biochemistry compared to placebo in patients with biopsy-proven nonalcoholic…
- Trial name
- NCT02442687
- Testing
- JKB-121: 5 mg twice daily, JKB-121: 10 mg twice daily
- Where
- 8 sites in United States
- Volunteers
- 65 people
- Sponsor
- Manal Abdelmalek
NAFLD, Overweight and Obesity
The Acute Effects of Eucaloric and Hypocaloric Carbohydrate Restriction on Liver Fat Content and Metabolism in Obese Individuals
The primary aim of this study is to investigate the acute changes in liver fat content in response to a fixed carbohydrate restriction (i.e.
- Conditions
- NAFLD, Overweight and Obesity, Metabolic Syndrome, Diabetes
- Trial name
- FixedCarb (NCT05643521)
- Testing
- Dietary composition of macronutrients and calories
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Hvidovre University Hospital
Non-alcoholic Fatty Liver Disease
Hepatic Inflammation and Physical Performance in Patients With NASH
The aim of the study is to examine the influence of hepatic inflammation or damage on physical performance (maximal oxygen uptake, VO2max) depending on the histologic state of the liver.
- Trial name
- HELP (NCT02526732)
- Testing
- individual training program
- Where
- Germany
- Volunteers
- 44 people
- Sponsor
- Priv.-Doz. Dr. J. Schattenberg
Non-alcoholic Fatty Liver Disease
Fructose and Liver Diseases in Youth: Help Them FLY
Obesity has been increasing all over the world. This has lead to a significant increase of a liver disease in children called non-alcoholic fatty liver disease (NAFLD).
- Trial name
- FLY (NCT05528471)
- Testing
- Dietary intervention
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- University of Alberta
Non-Alcoholic Fatty Liver Disease, Diabetes Mellitus
Iron Depletion Therapy for Type 2 DM and NAFLD
The purpose of this study is to find out whether lowering the amount of iron in the body will result in less resistance to insulin and improved liver function in patients with type 2 diabetes mellitus and non-alcoholic fatty…
- Trial name
- NCT00230087
- Testing
- blood donation
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.